Moderna, Inc. revenue by segment MRNA

Annual Quarterly

Moderna, Inc. splits its revenue into 7 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was COVID19 at $91.0 million, 63% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Jun 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024	Q3 FY2024 Sep 30, 2024
Revenue	2,228	145	389	678	1,016	142	108	966	1,862
Product Sales	—	—	—	—	—	114 share 80.3%	—	—	—
COVID19	—	91 -20.2% share 62.8%	345 +310.7% share 88.7%	642 -30.4% share 94.7%	971 -46.4% share 95.6%	114 share 80.3%	84 share 77.8%	923 share 95.5%	1,810 share 97.2%
Product And Service Other	—	—	—	32 share 4.7%	—	28 share 19.7%	22 share 20.4%	—	42 share 2.3%
Stand Ready Manufacturing	—	31 +82.4% share 21.4%	32 +166.7% share 8.2%	—	20 share 2.0%	17 share 12.0%	12 share 11.1%	—	—
Collaboration Arrangement Including Arrangements With Affiliate	—	15 +275.0% share 10.3%	5 +400.0% share 1.3%	1 -92.3% share 0.1%	7 -75.0% share 0.7%	4 share 2.8%	1 share 0.9%	13 share 1.3%	28 share 1.5%
RSV	—	3 share 2.1%	7 share 1.8%	4 -73.3% share 0.6%	2 -80.0% share 0.2%	—	—	15 share 1.6%	10 share 0.5%
Grant	—	2 -60.0% share 1.4%	—	2 -80.0% share 0.3%	14 +100.0% share 1.4%	5 share 3.5%	1 share 0.9%	10 share 1.0%	7 share 0.4%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: MRNA (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Cambridge, MA
SEC filer status: Large accelerated filer
SEC CIK: 1682852
Former names: Moderna Therapeutics, Inc. (until Aug 24, 2016)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.